---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Bone health management"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Bone health management. Topics: Consensus guideline: fracture risk, densitometry, calcium, and vitamin D; Bone health guideline: assessment and first-line interventions; Bone health guideline: non-pharmacological and pharmacological statements with panel agreement; Bone health guideline: limited evidence for bisphosphonates; 2 further topics. 6 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description/bone-health-management"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Bone health management

<a id="heading-2.2.2.1.5"></a>

## 2.2.2.1.5 Bone Health Management

<a id="topic-2.2.2.1.5-1"></a>

### Consensus guideline: fracture risk, densitometry, calcium, and vitamin D

> “There is higher risk of fracture due to immobility and use of anticonvulsants. If fracture occurs, consider bone density (DEXA) scan and referral to endocrine specialist (in addition to aggressive screen of calcium, vitamin D intake and 25-OH vitamin D levels).”
> “Ensure supplemental vitamin D intake: 600–1000 IU or more daily. Target serum levels of 25-OH-vitamin D greater than 30–40 ng/mL.”
> “With age, concern for low bone mineral mass coupled with long-term use of particular anticonvulsants raises the risks for osteoporosis and bone fractures”

Source: [Fu et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7488790/)

<a id="topic-2.2.2.1.5-2"></a>

### Bone health guideline: assessment and first-line interventions

> “Agreement was reached on 39 statements which were formulated from 41 statements and 11 questions.”
> “A baseline densitometry assessment should be performed with accommodations made for size, with the frequency of surveillance determined according to individual risk.”
> “Increasing physical activity and initiating calcium and vitamin D supplementation when low are the first approaches to optimizing bone health in Rett syndrome. If individuals with Rett syndrome meet the ISCD criterion for osteoporosis in children, the use of bisphosphonates is recommended.”

Source: [Jefferson et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4743907/)

<a id="topic-2.2.2.1.5-3"></a>

### Bone health guideline: non-pharmacological and pharmacological statements with panel agreement

| Intervention | Statement | Panel agreement, n/N (%) |
| --- | --- | --- |
| Physical activity | “Increase physical activity in order to increase muscle strength and bone density” | “34/34 (100)” |
| Standing frame | “Use a standing frame for at least 30 minutes a day” | “28/33 (84.8)” |
| Targeted exercise | “Where mobility is limited, targeted exercise such as body weight supported treadmill or assisted walking is recommended” | “31/32 (96.9)” |
| Dietary calcium | “If calcium intake is low, increase dietary intake of calcium rich or calcium fortified foods” | “31/32 (96.9)” |
| Bisphosphonate indication | “Bisphosphonates should be used if the International Society for Clinical Densitometry criteria for osteoporosis in children and adolescents are fulfilled” | “17/23 (73.9)” |
| Bisphosphonate reassessment | “Reassess bone mineral content and areal bone mineral density one year after Bisphosphonate therapy to decide on further therapy” | “24/26 (92.3)” |
| Hormonal contraception | “If hormonal intervention for regulation of the menstrual cycle is needed, use of Depot medroxyprogesterone acetate (DMPA) should be avoided” | “21/21 (100)” |

Source: [Jefferson et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4743907/)

<a id="topic-2.2.2.1.5-4"></a>

### Bone health guideline: limited evidence for bisphosphonates

> “Whilst the group agreed that bisphosphonate therapy may be indicated, several panel members did make note of the lack of evidence for efficacy and safety of bisphosphonate use in RTT and that its mechanism of action may be different from disorders such as osteogenesis imperfecta in which its use is frequent”

Source: [Jefferson et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4743907/)

<a id="topic-2.2.2.1.5-5"></a>

### Zoledronate: retrospective national center cohort

> “Nine patients (23%) received zoledronate, for a mean 2 years. The mean age at zoledronate initiation was 9.7 ± 2.3 years. Four completed two DXA scans (pre- and post-treatment); the mean BMD Z-score improved from −2.2 ± 0.9 to −1.4 ± 0.9 after treatment.”
> “Poor L1–4 BMD Z-scores were associated with poor mobility scores (p = 0.05) and valproate treatment (p = 0.016).”

Source: [Levy-Shraga et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12602358/)

<a id="topic-2.2.2.1.5-6"></a>

### Zoledronic acid: annual infusion in children with cerebral palsy and Rett syndrome

> “27 children under 18 years (19 with cerebral palsy and 8 girls with Rett syndrome confirmed by MCEP2 mutation) were treated with an annual injection of 0.1 mg/kg (max 4 mg) of ZA.”
> “No fractures have been observed in our cohort since the first infusion.”
> “Side effects (flu-like syndrome and hypocalcemia) were more common in younger patients and after the first infusion.”

Source: [Wiedemann et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30554334/)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
